TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Serum ferritin change from baseline to end-of-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in c-FGF23 from baseline to end-of-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median E2 24 h average concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of participants with E2 concentrations exceeding 20 pg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain pressure sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early moderate delirium (24h postoperatively)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perceived stigma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived cognitive impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: clinically significant insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: clinically significant nightmares
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: perceived dizziness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of selgantolimod
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-dependent pharmacodynamic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global health status/QoL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incomplete Complete Response (ICR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of dentin removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: untouched canal wall (UCW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean load at failure of premolars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sunburn rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sun protection habits index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from a paramedic on scene to thrombolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombolysis delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: velocity of COP oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of COP oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Men's attendance at ANC services
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Acceptance of HIV testing by men
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment success percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: P3 amplitude changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MoCA score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: ADAS-Cog score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Serum levels of APP and Aβ1-42 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in COVID-19 anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in health anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in anxiety sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in somatosensory amplification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of motion artifacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total shoulder score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cleaning efficiency of root canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Self-reported consecutive 7-day PPA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biochemically verified abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Death or myocardial infarction (MI) rate
Endpoint domain: Mortality/survival
Primary endpoint: Lobe involvement percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of pulmonary lesions and consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mental Quality of Life Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean quality of recovery‐40 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: GSRS total score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: DASS‐21 anxiety score reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ipsilateral forelimb lameness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed cerebral ischemia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Radiographic vasospasm incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improvements in overall quality of sexual activities
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Favorable clinical outcome (mRS ≤ 2 at 90 days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentages of contaminated surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak knee external adduction moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: peak vertical ground reaction forces (vGRFs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: peak loading rate of vertical ground reaction forces (vGRFs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CPR skills acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appropriate compression depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian morphology improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Conversations about functional or physical performance
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Freedom from regional nodal recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Length of Hospital Stay (LOH)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Ulcer recurrence reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VCSS after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mandibular crowding improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: day time frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: bladder control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: VLDL ApoC-III levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: VLDL ex-vivo triglyceride transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: final overjet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final PAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of delirium (D-O-M scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed time-to-first deterioration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvements in LCSS measures of symptom burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in EQ-5D VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oxyhemoglobin activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of any stroke
Endpoint domain: Mortality/survival
Primary endpoint: Risk of small-vessel occlusion
Endpoint domain: Mortality/survival
Primary endpoint: Health-related internet use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: combined kidney outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in WISCI‐II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WC implementation index scores
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Evidence-based intervention scores
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 24-hour sensor glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postprandial sensor glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional connectivity between the medial prefrontal cortex and default mode network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FOIS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time <30 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in composition and heterogeneity of circulating innate immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Return to racing
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: week 9 remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insecticidal efficacy
Endpoint domain: Mortality/survival
Primary endpoint: Pain disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short form 36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in total calculus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in gingival health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total T4 exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax of semaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diameter of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linking to mental health services
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in log viral load at day 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean and maximal transvalvular gradient values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of severe PPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postoperative opioid pill consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SDANN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of patients with NRS score ≤3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of outlets that removed SSBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Support for SSB removal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: distant recurrence risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Graft fixation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of sutures used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Nasolabial angle improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose of potentially inappropriate medications (PIMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events following deprescribing
Endpoint domain: Adverse events/effects
Primary endpoint: Inter-rater agreement (IRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gastrocnemius muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ankle joint range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: cross‐sectional muscle area of the lower leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mortality over 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Major cardiovascular events at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of HIV drug resistant mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: visual memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attention to less salient stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: focused attention during naturalistic tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of documented interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain level after episiotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal isometric voluntary contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocytes and lymphocytes levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sUA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean peak uUA excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: cumulative de-qi sensation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensation of soreness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: electrical resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of spontaneous abortion
Endpoint domain: Mortality/survival
Primary endpoint: Mean gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute change in median infarct volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of healthier items ordered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-management competencies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reestablishment of the normal anatomic relationship of the TMJ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Aesthetics
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cure rates for genital warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: indexed minimal LA volume (LAVImin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LA reservoir strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to disability progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of stepwise ramp increase during the splitting phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appendiceal visualization grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of perforated appendicitis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of false-negative diagnoses
Endpoint domain: Adverse events/effects
Primary endpoint: Total Lung Ultrasound (LUS) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in LPIR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: non‐routine medical care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: speed performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of direction (COD) performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreases in ED and MD risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body appreciation improvements
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: minimising immunisation pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of late recurrence
Endpoint domain: Mortality/survival
Primary endpoint: therapeutic efficacy of NAPSO doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 75% reduction in the Eczema Area and Severity Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 3-point reduction in weekly average daily peak daily pruritus numerical rating scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 4-point reduction in weekly average daily peak daily pruritus numerical rating scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough reflex thresholds (logC2 and logC5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urge-to-cough threshold (LogCu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal rigidity (G) difference pre- and post-CXL treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-5 treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of type A endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Serum E2 and P levels on the day of hCG injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ratio of AEA serum level to ARA intake (AEA/ARA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood stream infections
Endpoint domain: Adverse events/effects
Primary endpoint: generic measure of QoL (SF‐6D utility scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: cancer‐specific QoL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Mean pruritus scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reoperations on the ipsilateral side
Endpoint domain: Adverse events/effects
Primary endpoint: SI (Stimulation Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DI (Disposal Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bacterial growth in oral flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Grade ?2 breast erythema
Endpoint domain: Adverse events/effects
Primary endpoint: Grade ?2 dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 2 hyperpigmentation
Endpoint domain: Adverse events/effects
Primary endpoint: Post-discharge follow-up response rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sufentanil consumption within 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of PONV
Endpoint domain: Adverse events/effects
Primary endpoint: mean time to first passage of flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes